Research on measurable signals of health and disease. Covers ultrasound imaging pipelines, fetal-distress detection, cancer monitoring, and fatigue biology.
The Emory research team aims to identify protein biomarkers that correlate with ALS onset and progression. Developing such biomarkers could enable early diagnosis, disease monitoring, and potential prevention of the disease.
Researchers found that smokeless tobacco users are exposed to higher amounts of tobacco-specific nitrosamines than cigarette smokers. The study highlights the dangers of smokeless tobacco and suggests that nicotine replacement therapy may be a safer alternative.
Researchers discovered that blood levels of protein ST2 indicate the presence of heart failure and predict the risk of death, even among patients without heart failure. A combination of ST2 with other biomarkers provides the most accurate prediction for all study participants.
Researchers have identified a potential biomarker, urinary neutrophil gelatinase-associated lipocalin (uNGAL), to predict acute kidney injury (AKI) in critically ill children. The study found that uNGAL levels increased 48 hours before a jump in serum creatinine levels, suggesting its potential as an early warning system for AKI preven...
The new criteria focus on a clinical core of early and significant episodic memory impairment, incorporating biomarker-based tests. Validation studies are necessary to optimize sensitivity, specificity, and accuracy.
Researchers introduce novel methods for evaluating patients with non-alcoholic fatty liver disease (NAFLD), including a blood test to determine caspase three-generated cytokeratin 18 fragment levels. These tests may help differentiate NASH from simple steatosis and predict treatment outcomes, potentially improving patient care.
The AACR-FDA-NCI Cancer Biomarkers Collaborative aims to integrate predictive biomarkers into clinical trials, addressing the translation of cancer knowledge into medical practice. The collaborative will develop guidelines for biomarker validation, informing policies as part of the FDA's Critical Path Initiative.
A Sandia National Laboratories handheld device determines if a patient has gum disease and quantifies its advancement in minutes from a tiny saliva sample. The device's technology also shows promise for detecting biotoxins, improving prostate and breast cancer diagnosis, and measuring animal serum in vaccines.
Biosite has identified a combination of three biomarkers that performed better in assessing risk of sepsis progression. The sepsis biomarker panel may aid in the rapid assessment of patients presenting to the emergency department with signs and symptoms of sepsis.
Researchers at Temple University have found early indicators of inflammation in work-related injuries caused by repetitive motion, signaling potential warning signs for debilitating conditions like carpal tunnel syndrome. The study's findings could lead to early detection and prevention of these conditions.
Researchers at UT Southwestern Medical Center have found a new biomarker test that can predict the recurrence of bladder cancer in patients. The test uses molecular biomarkers to identify patients who are more likely to experience cancer recurrence, allowing for personalized treatment options.
A new study has identified a set of biomarkers using proteomics that could help diagnose myelodysplastic syndromes (MDS) and reduce the need for bone marrow biopsies. The findings, reported in the Proceedings of the National Academy of Sciences, used serum proteomic profiling to distinguish between MDS patients and healthy controls.
Scientists found that persons with high multimarker scores had a risk of death four times as great and a risk of major cardiovascular events almost two times as great as those with low scores. The study used 3209 participants for 10 years, measuring 10 novel biomarkers in addition to established risk factors.
A study suggests that even commonly used biomarkers are limited in their ability to predict cardiovascular risk. BNP and urinary albumin content were found to be the most useful in predicting future events, but only slightly improved predictions based on conventional risk factors.
Scientists at Cornell University have discovered a panel of 23 protein biomarkers in cerebrospinal fluid that can identify patients living with Alzheimer's disease. The biomarkers, known as a 'fingerprint,' were validated through autopsy-proven tests and showed high sensitivity and accuracy.
Researchers have identified amylase, an enzyme in saliva, as a biochemical marker linked to sleep loss. Flies subjected to prolonged sleep deprivation showed increased amylase levels, similar to humans who were kept awake for extended periods. The discovery aims to develop diagnostic tools and improve understanding of sleep disorders.
Researchers at Pacific Northwest National Laboratory have discovered 176 proteins associated with plague virulence, offering promising leads for improved disease detection and treatment. The study's findings may also guide the development of new vaccines and therapies to combat the deadly disease.
Researchers at Emory University's Winship Cancer Institute have identified a novel biomarker called 'soluble attractin' that is elevated in patients with malignant astrocytomas. This protein plays a key role in the migration and recurrence of brain tumors, making it a promising target for future therapeutic intervention.
Researchers at Columbia University Medical Center found that elevated inflammatory biomarkers, such as Lp-PLA2 and hs-CRP, are associated with increased risk of recurrent stroke and mortality after a first stroke. The study's findings may lead to the use of prophylactic treatments to reduce stroke risk in people with elevated biomarkers.
The IU and Purdue Analytical Proteomics Team has been awarded a grant to develop standardized proteomics methodologies to discover proteins relevant to cancer. The team will work with cancer researchers and clinicians at the IU School of Medicine, as well as experts in statistical and computer analysis.
A study analyzing 13 biomarkers found that combinations of neuroendocrine and immune markers were associated with high-risk pathways in men, while systolic blood pressure was linked to female high-risk pathways. Recursive partitioning identified the importance of biological regulatory systems in predicting mortality in later life.
A new biomarker predicting survival in colorectal carcinomas has been discovered, with thymidylate synthase levels in the nucleus and cytoplasm identified as critical markers. The ratio of nuclear to cytoplasmic TS levels also predicts decreased survival, revealing a new potential biomarker for patients with worse prognosis.
The Osteoarthritis Initiative (OAI) has released its first set of data, featuring images and clinical outcome information for nearly 5,000 participants at risk of knee osteoarthritis. The data will facilitate the discovery of biomarkers for development and progression of OA.
A study published in Biochemistry reveals that damage to proteins caused by oxidative stress is linked to a natural byproduct called nitration, which could be used to predict the earliest stages of brain impairment. The research uses the most detailed proteomic analysis of a mammalian brain to date.
Researchers found that certain fatty acid ethyl esters (FAEEs) in meconium are indicative of fetal exposure to alcohol during pregnancy. The presence of these biomarkers was significantly higher in infants exposed to alcohol, suggesting potential as a reliable indicator of fetal alcohol effects.
New research finds ancient oil droplets containing biomarkers from eukaryotes and cyanobacteria that lived before the planet's glaciation, contradicting previous theories. The study suggests oxygen was produced long before the atmosphere became oxygenated, supporting life in extreme conditions.
Researchers have identified new biomarkers that correlate with patient response to anti-TNFá therapy, improving the treatment of spondylarthritis. The study found changes in synovial tissue features, such as macrophage and PMN cell changes, associated with disease activity and treatment effectiveness.
Researchers have developed a completely penetrant mouse model of head and neck squamous cell carcinoma, recapitulating the human disease at both pathological and molecular levels. The model enables testing of combinations of targeted therapies and prevention approaches for HNSCC.
Precision biochemistry techniques track DNA damage in fish, identifying low-level lesions that correlate with pollution. These biomarkers can provide a direct measure of contaminant impact and assess pollution remediation efforts.
Scientists from the University of Florida's Institute on Aging found that reducing calories by 8% and exercising moderately extended lifespan and improved liver function in rats. This discovery suggests that even slight calorie moderation can have significant effects on health, with potential implications for human aging.
A UK study found that saliva can be tested for signs of periodontal disease, a condition characterized by persistent inflammation and tissue breakdown. The research team identified biomarkers in saliva that could aid in diagnosing and monitoring the disease.
Researchers have identified a multi-marker panel of 20 proteins that correctly recognize over 98% of serum samples from women with ovarian cancer, offering higher diagnostic power than any other published assay. The study uses novel technology to analyze multiple proteins in a single drop of blood or serum and aims to develop this scre...
Researchers at Purdue University have developed a fast chemical-analysis tool called desorption electrospray ionization (DESI) that can detect cancer, explosives and biomarkers. The technology has numerous promising uses in fields such as airport security, medical diagnostics and disease detection.
Scientists have developed a standardized saliva RNA test for oral cancer detection, showing high accuracy rates in detecting oral cancer. The test has been confirmed to be highly accurate in identifying four saliva oral cancer RNA biomarkers, reducing mortality and morbidity for oral cancer patients.
Researchers have identified new molecular indicators of aging in the skin that could be used to evaluate anti-aging therapies. The biomarkers are changes to the DNA of cellular organelles called mitochondria and correlate with the aging process.
Several biomarkers emerged as potentially clinically useful in predicting CAD-related and all-cause death. Increases in plasma levels of IL-6 and total homocysteine were associated with higher risks of death in patients with known CAD.
Researchers used high-tech brain imaging and measurement of beta-amyloid protein fragments in cerebrospinal fluid to detect Alzheimer's disease. The study found that greater amounts of beta-amyloid containing plaques were associated with lower levels of amyloid-beta 1-42, a major component of amyloid plaques.
Researchers at Yale University School of Medicine used Automated Quantitative Analysis (AQUA TM ) technology to standardize biomarker detection methods. The study found that antibody concentration can dramatically alter the relationship between biomarker levels and clinical outcome, particularly for breast cancer biomarkers.
A study by David L. Rimm and colleagues found that high biomarker antibody concentrations were associated with low patient survival in breast cancer patients, while low concentrations were linked to good outcomes. Another study examined the impact of long-term storage on circulating DNA levels in lung cancer patients.
Researchers found two biomarkers, sVCAM-1 and NT-proBNP, significantly predict recurrent ischemic stroke risk in patients. High levels of these markers are associated with a 3.6 times increased risk, indicating potential new therapeutic targets for blood pressure-lowering therapies.
Researchers have identified a strong biomarker, MDM2, that predicts more aggressive forms of prostate cancer. This overexpression is associated with an increased chance of metastasis and death from the disease.
A team of researchers developed a tracer molecule to highlight beta-amyloid in PET brain scans, aiming to diagnose Alzheimer's disease earlier. PET biomarkers could also evaluate the effects of drugs on the brain, potentially improving treatment outcomes for neurodegenerative conditions.
A Yale University study will examine dietary calcium insufficiency in inner city infants, highlighting the alarming trends of decreased calcium intake over the past 30 years. The research aims to establish guidelines for calcium in infants below age three and predict a 10-20% prevalence of abnormal biomarkers.
Researchers emphasize the need for early detection and monitoring of alcohol abuse to prevent dependence issues. Emerging biomarkers, such as genetic analysis, hold promise for accurate diagnosis and treatment compliance.
A recent study published in Archives of Neurology suggests that variations in p-tau 231 levels can predict the structural progression of Alzheimer's disease. The biomarker has been shown to discriminate between AD patients and those with other neurodegenerative disorders, with high accuracy in detecting early-stage disease.
A recent study has associated high expression of interferon-inducible genes with increased disease severity in SLE patients, including kidney disease. The findings suggest that determining the expression of these genes may help select patients for clinical studies.
A new painless diagnostic test for Sjögren's syndrome could be available in two to three years, promising faster diagnosis and reduced severity of symptoms. The test involves analyzing teardrops collected from patients' eyes, which may help identify specific protein biomarkers for the disease.
Researchers found abnormally low levels of N-acetylaspartate in methamphetamine users, but elevated choline levels in early abstainers, suggesting some degree of normalization over time. The study's findings have important implications for understanding addiction and substance abuse treatment.
Researchers have found a novel biomarker, neutrophil gelatinase-associated lipocalin (NGAL), that can detect kidney failure in children after cardiac surgery in as little as two hours. This early diagnosis enables timely administration of effective therapeutic measures to prevent further complications.
A new study published in The Lancet identified a biomarker NGAL that can detect kidney failure hours after cardiac surgery, offering hope for earlier diagnosis and treatment. The research found high concentrations of NGAL in urine and blood samples within two hours of surgery, indicating the presence of kidney failure.
Researchers identified protein biomarkers in amniotic fluid linked to preterm labor, predicting success of cervical stitching. The study also found additional biomarkers suggesting other causes of preterm birth.
Scientists at Northwestern University have developed a new diagnostic test for Alzheimer's disease using bio-bar-code amplification technology. The test can detect miniscule amounts of a toxic protein in human cerebrospinal fluid, which may be responsible for early neurological deterioration.
A $9.7 million grant led by Fred Hutchinson Cancer Center aims to create reliable and inexpensive blood tests for early cancer detection. The collaboration involves institutions worldwide, with a focus on identifying serum biomarkers and protein patterns to detect disease at an early stage.
Researchers at the University of Pittsburgh identified abnormal levels of protein erythrocyte-C4d in patients with lupus, showing high diagnostic sensitivity and specificity for the disease. This finding may lead to improved diagnosis and treatment options for patients with lupus.
Researchers at OHSU have discovered a possible method for early detection and prevention of premature birth by identifying biomarkers associated with intra-amniotic infections in both animal and human studies. The breakthrough technology has the potential to save young lives and may lead to significant health benefits.
Researchers have discovered biomarkers for ALS in cerebrospinal fluid, which could enable rapid diagnosis and prompt treatment. These biomarkers have high sensitivity and specificity, and may be used to monitor drug effectiveness in clinical trials.
A Medical College of Georgia study aims to identify specific protein markers in the blood that indicate how ovarian cancer responds to therapy. By analyzing changes in protein expression over time, researchers hope to develop a better understanding of the disease process and create more effective screening tests.
The Osteoarthritis Initiative aims to identify people at risk for OA and monitor disease progression using biological markers. The study will enroll 5,000 adults over five years, collecting data on joint pain, limited movement, and cartilage loss.
Researchers at Pacific Northwest National Laboratory have identified a vast array of 4,000 distinctive proteins in human blood plasma, surpassing previous reports by 10 times. This significant advance paves the way for the early detection of cancer and other diseases.
Elevated PlGF levels in patients with acute coronary syndromes (ACS) and acute chest pain indicate a significantly increased risk of heart attack or death at 30 days. Measuring PlGF levels may provide a powerful clinical biomarker for vascular inflammation and adverse outcome in ACS patients.